Emerging and receding risks of therapeutic regimens for haemophilia.
During the past two decades, the improvement of therapeutic agents for the management of haemophilia has created the opportunity for individuals with haemophilia to live normal lives. However, in some instances, the progress made has been accompanied by emergence of unexpected risks and other new complications. A number of viruses have either emerged, or become greater risks to people with haemophilia. In addition, the drive of many countries towards self-sufficiency in blood products may in fact be endangering people with haemophilia by restricting blood donation to a pool of donors with high infection risk, discouraging commercial interests from developing safer products, and discouraging use of 'foreign' products even where that may be the safer option. Gene therapy for haemophilia, although an encouraging new treatment, has brought with it a number of adverse events, including risk of virus infection and development of carcinomas. The risk of inhibitors is still the most important problem for people with haemophilia, and a recent report showed that the type of factor concentrate does not impact significantly on this risk. Despite the advent of new and promising treatments for haemophilia, heathcare providers must be alert to new risks posed by them.
Farrugia
A
A
Office of Devices, Blood and Tissues, Australian Therapeutic Goods Administration, Australia. bevatt@mindspring.com
Manno
C S
CS
Evatt
B L
BL
D001779:Blood Coagulation Factors / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000600:supply & distribution; D016913:Blood Component Transfusion / Q000379:methods; D003257:Consumer Product Safety; D015316:Genetic Therapy / Q000009:adverse effects; D006291:Health Policy; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D012307:Risk Factors; D014777:Virus Diseases / Q000150:complications
D001779:Blood Coagulation Factors